1 – 7 of 7
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Age-related pathological impairments in directly reprogrammed dopaminergic neurons derived from patients with idiopathic Parkinson's disease
(
- Contribution to journal › Article
- 2017
-
Mark
Predictive Markers Guide Differentiation to Improve Graft Outcome in Clinical Translation of hESC-Based Therapy for Parkinson's Disease
(
- Contribution to journal › Article
- 2013
-
Mark
Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: Effects of combined treatment and possible mechanisms of action.
(
- Contribution to journal › Article
- 2012
-
Mark
The serotonin system: a potential target for anti-dyskinetic treatments and biomarker discovery.
(
- Contribution to journal › Article
- 2011
-
Mark
Putaminal Upregulation of FosB/Delta FosB-Like Immunoreactivity in Parkinson's Disease Patients with Dyskinesia
(
- Contribution to journal › Article
- 2010
-
Mark
Deuterium substitutions in the L-DOPA molecule improve its anti-akinetic potency without increasing dyskinesias
(
- Contribution to journal › Article
- 2009
-
Mark
Plastic effects of L-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia.
(
- Contribution to journal › Article